Transfusion of convalescent plasma from patients with COVID -19

Authors

  • César A. Galván Unidad Funcional de Alergia, Asma e Inmunología (UFAAI) del Instituto Nacional de Salud del Niño (INSN), Lima, Perú. Sociedad Peruana de Inmunología (SPI), Lima, Perú. Médico cirujano; especialista en Inmunología y Alergología https://orcid.org/0000-0003-3517-3051
  • Crhistian Toribio-Dionicio Sociedad Peruana de Inmunología (SPI), Lima, Perú. Facultad de Medicina, Universidad Nacional Mayor de San Marcos (UNMSM), Lima, Perú. Médico cirujano https://orcid.org/0000-0002-3198-5549
  • Marco Álvarez-Ángeles Sociedad Peruana de Inmunología (SPI), Lima, Perú. Instituto de Hemaféresis y Terapia Celular (IHEMATEC), Lima, Perú. tecnólogo médico, magíster en Ciencias https://orcid.org/0000-0002-2122-4826
  • Oscar Alama-Bazán Servicio de Bioquímica e Inmunoquímica del Hospital Nacional Alberto Sabogal Sologuren (HNASS), Lima, Perú. Asociación Médica Peruana de Patología Clínica (AMPPC), Lima, Perú. Médico cirujano especialista en Patología Clínica. https://orcid.org/0000-0003-2649-307X
  • Luis Sánchez-Ramírez Asociación Médica Peruana de Patología Clínica (AMPPC), Lima, Perú. Banco de Sangre del Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Perú. Médico cirujano especialista en Patología Clínica. https://orcid.org/0000-0002-6774-7948

DOI:

https://doi.org/10.17843/rpmesp.2020.374.5767

Keywords:

COVID-19, Plasma, MERS Virus, SARS Virus

Abstract

There is currently no vaccine available and no specific medication against Coronavirus 2019 disease (COVID-19). The treatment is mainly based on support measures. In this context, several potentially useful therapies have been approved for use in clinical trials, such as convalescent plasma transfusion (CPT). PubMed was searched for studies on convalescent plasma and COVID-19, SARS or MERS. Studies on clinical efficacy in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increase of neutralizing antibodies, decreased mortality and absence of adverse events during and after treatment. We found 13 studies on this type of treatment used in patients with severe and critical COVID-19. Despite limitations regarding methodology, number of patients and the protocols for the analysis of donors’ convalescent plasma, patients who received CPT showed clinical improvement, improvement of ventilatory patterns, resolution of lung injuries, decreased mortality, improvement of laboratory parameters, increase of neutralizing antibodies, decreased viral load and low frequency of adverse events.

Downloads

Download data is not yet available.

Published

2020-11-09

Issue

Section

Review

How to Cite

1.
Galván CA, Toribio-Dionicio C, Álvarez-Ángeles M, Alama-Bazán O, Sánchez-Ramírez L. Transfusion of convalescent plasma from patients with COVID -19. Rev Peru Med Exp Salud Publica [Internet]. 2020 Nov. 9 [cited 2024 Apr. 23];37(4):746-54. Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/5767

Most read articles by the same author(s)